mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
Phase Ⅱ Trial to Investigate the Efficacy and Safety of mFOLFIRINOX in Patients With Metastatic Pancreatic Cancer in China
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Li Yuhong, MD, Ph D
- Email: liyh@sysucc.org.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Sun Yat-sen University Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients have provided a signed Informed Consent Form
- ECOG performance status of 0-1
- BMI ≥ 18.5
- Age: 18-65 years old
- Histologically confirmed diagnosis of metastatic pancreatic cancer
- No prior palliative chemotherapy
- Measurable disease in at least 1 diameter by CT scan or MRI as per RECIST 1.1 criteria
- Life expectancy ≥ 3 months
Patient has adequate bone marrow and organ function
- Absolute Neutrophil Count (ANC) ≥ 2.0 x 109/L
- Platelets ≥ 90 x 109/L
- Hemoglobin ≥ 90 g/L
Patient has adequate liver function
- AST and ALT not more than 2.5 times ULN (not more than 5.0 times ULN if there is liver metastasis)
- Serum bilirubin ≤ 1.2 x ULN
- Creatinine ≤ 1.25 times ULN
- Good compliance
Exclusion Criteria:
- Pregnant or lactating women
- Brain metastasis or only with bone metastasis.
- Patients with severe gastrointestinal hemorrhage which need frequent blood transfusions.
- Refuse to take appropriate contraceptive measures (including male patients).
- Allergic to Oxaliplatin, Irinotecan, Leucovorin or 5-Fluorouracil.
- Severe systemic disease out of control such as unstable or uncompensated respiratory, cardiac, liver, renal diseases.
- Patient has a concurrent malignancy or has a malignancy within 5 years of study enrollment, (with the exception of non-melanoma skin cancer or cervical carcinoma in situ).
- Psychiatric illness that would prevent the patient from giving informed consent.
- Patient is concurrently using other antineoplastic agent
- Patient has used investigational antineoplastic agent within 4 weeks prior to entry.
- Known HIV-positivity.
- No history of chronic diarrhea, nausea or vomit.
- No ≥ grade 2 sensory peripheral neuropathy.
- A history of transmural myocardial infarction (within 6 months prior to entry), congestive heart failure, and unstable angina.
- Infectious disease or inflammation with body temperature ≥ 38 ℃.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: FOLFIRINOX
Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
|
Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Disease control rate
Time Frame: Up to 24 weeks
|
Up to 24 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression free survival
Time Frame: From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
From the date of first drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
|
Overall survival
Time Frame: From the date of first drug administration until the date of death, assessed up to 60 months
|
From the date of first drug administration until the date of death, assessed up to 60 months
|
|
|
Number of participants with AEs and SAEs as a measure of Safety
Time Frame: Each follow up visit, assessed up to 24 weeks
|
Safety data will be assessed at each study visit using NCI CTCAE version 3.0
|
Each follow up visit, assessed up to 24 weeks
|
|
EORTC QLQ-C30
Time Frame: Each follow up visit, assessed up to 24 weeks
|
Quality of life will be assessed at each study using EORTC QLQ-C30
|
Each follow up visit, assessed up to 24 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Li Yuhong, MD, Sun Yat-sen University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protective Agents
- Topoisomerase Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Oxaliplatin
- Leucovorin
- Irinotecan
Other Study ID Numbers
Other Study ID Numbers
- PAN-321
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.